| 211 |
Risk Factors for Recurrent CMV Reactivation in CMV Seropositive Recipients Following T Cell Depleted Haematopoietic Stem Cell Transplantation |
2014 |
| 212 |
The role of Circulating Tumor Cells (CTCs) in
Predicting the Response of Primary (Neoadjuvant)
Chemotherapy and its Impact as a Prognostic Factor in
Early Breast Cancer
|
2014 |
| 213 |
The role of Circulating Tumor Cells (CTCs) in
Predicting the Response of Primary (Neoadjuvant)
Chemotherapy and its Impact as a Prognostic Factor in
Early Breast Cancer
|
2014 |
| 214 |
The role of Circulating Tumor Cells (CTCs) in Predicting the Response of Primary (Neoadjuvant) Chemotherapy and its Impact as a Prognostic Factor in Early Breast |
2014 |
| 215 |
The role of Circulating Tumor Cells (CTCs) in Predicting the Response of Primary (Neoadjuvant) Chemotherapy and its Impact as a Prognostic Factor in Early Breast |
2014 |
| 216 |
• Comparative study of Gemcitabine versus Cisplatin concurrent with radiotherapy for locally advanced head and neck cancer |
2014 |
| 217 |
• Comparative study of Gemcitabine versus Cisplatin concurrent with radiotherapy for locally advanced head and neck cancer |
2014 |
| 218 |
ECF with Infusional Fluorouracil for 5 Days in Locally Advanced and Metastatic Gastric Cancer, Is It Better than the Standard?
|
2013 |
| 219 |
ECF with Infusional Fluorouracil for 5 Days in Locally Advanced and Metastatic Gastric Cancer, Is It Better than the Standard?
|
2013 |
| 220 |
ECF with Infusional Fluorouracil for 5 Days in Locally Advanced and Metastatic Gastric Cancer, Is It Better than the Standard? |
2013 |
